Use of an indirect inhibitor of factor Xa in combination with a compound with anti-platelet aggregation activity and pharmaceutical compositions comprising said agents

摘要

The invention relates to the use of synthetic pentasaccharide methyl-O-(2-deoxy-2-sulphoamino-6-O-sulpho-alpha- D-glucopyranosyl)-1(1--4)-O-(beta-D-glucopyranosyluronic acid)-(1--4)-O-(2-deoxy-2-sulphoamino-3,6-di-O-sulpho-alpha-D- glucopyranosyl) )-(1--4)-O-(2-O-sulpho-alpha-L- idopyranosyluronic acid)-(1--4)-2-deoxy-2-sulphoamino-6-O- sulpho-alpha-D-glukopyranoside whose anion has the structure (B), or one of its pharmaceutically acceptable salts, as the indirect inhibitor of factor Xa, in combination with one or more compounds with anti-platelet aggregation activity antagonizing glycoprotein IIb/IIIa, selected from ethyl-N-(1-ethoxycarbonylmethylpiperidin- 4-yl)-N-{4-[4-{(N- ethoxycarbonylimino)(amino)methyl}phenyl]thiazol-2-yl}-3- aminopropionate and N-(1-carboxymethylpiperidin-4-yl)-N-{4-[4- {(amino)(imino)methyl}phenyl]thiazol-2-yl}-3-aminopropionic acid, and their pharmaceutically acceptable salts for the preparation of medicaments intended to prevent and to treat thromboembolic arterial diseases. Also disclosed are pharmaceutical compositions comprising said combination of active agents.